Interferon-gamma in the treatment of systemic sclerosis: A randomized controlled multicentre trial

British Journal of Dermatology

Volumn 139, Issue 4, 1998, Pages 639-648

  Grassegger, A ^a   Schuler, G ^b   Hessenberger, G ^c   Walder Hantich, B ^d   Jabkowski, J ^e   Macheiner, W ^f   Salmhofer, W ^g   Zahel, B ⁱ   Pinter, G ^h   Herold, M ^c   Klein, G ^e   Fritsch, P O ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d GENERAL HOSPITAL   (Austria)

^e ELISABETHINEN HOSPITAL   (Austria)

^f UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY OF GRAZ   (Austria)

^h GENERAL HOSPITAL KLAGENFURT   (Austria)

ⁱ KEPLER UNIVERSITY HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; RECOMBINANT GAMMA INTERFERON;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; ATRIOVENTRICULAR BLOCK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HEARING LOSS; HUMAN; IMMUNOTHERAPY; IMPOTENCE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; DERMATOLOGIC AGENTS; FEMALE; HUMANS; INTERFERON TYPE II; KIDNEY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC;

EID: 7844237877     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02460.x     Document Type: Article

References (31)

1. Arbeitsgruppe Sklerodermie der Arbeitsgemeinschaft für Dermatologische Forschung (ADF). Klinik der progressiven systemischen Sklerodermie (PSS). Multizentrische Untersuchungen an 194 Patienten. Hautarzt 1986; 37: 320-4.
2. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
3. Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953-83): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1978; 15: 276-83.
4. Seibold JR, Furst DE, Clements PJ. Treatment of systemic sclerosis by disease modifying agents. In: Systemic Sclerosis (Clements PJ, Furst DE, eds). Baltimore: Williams & Wilkins, 1996: 535-48.
5. Gelber AC, Wigley FM. Treatment of scleroderma. Curr Opin Rheumatol 1995; 7: 551-9.
6. Dau PC, Kahaleh MB, Sagabiel RW. Plasmapheresis and immunosuppressive drug therapy in scleroderma. Arthritis Rheum 1981; 24: 1128-36.
7. Steen VD, Medsger TA, Rodnan GP. D-Penicillamine therapy in systemic progressive sclerosis (scleroderma). A retrospective analysis. Ann Intern Med 1982; 97: 652-9.
8. Hunzelmann N, Anders S, Fierlbeck G et al. Systemic scleroderma. Multicenter trial of 1 year of treatment with recombinant Interferon gamma. Arch Dermatol 1997; 133: 609-13.
9. Freundlich B, Jimenez SA, Steen VD et al. Treatment of systemic sclerosis with recombinant interferon-γ. Arthritis Rheum 1992; 35: 1134-42.
10. Hein R, Behr J, Hündgen M et al. Treatment of systemic sclerosis with γ-interferon. Br J Dermatol 1992; 126: 496-501.
11. Kahan A, Amor B, Menkes CJ, Stauch G. Recombinant interferon gamma in the treatment of systemic sclerosis. Am J Med 1989; 87: 273-7.
12. Farmer RG, Gifford RW Jr, Hines EA Jr Prognostic significance of Raynaud's phenomenon and other clinical characteristics of systemic scleroderma. A study of 271 cases. Circulation 1960; 21: 1088-95.
13. Clements PJ. Measuring disease activity and severity in scleroderma. Curr Opin Rheumatol 1995; 7: 517-21.
14. Furst DE, Clements PJ, Harris R et al. Measurement of clinical change in progressive systemic sclerosis: a one-year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis 1979; 38: 356-61.
15. Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979; 22: 130-40.
16. Jimenez SA, Freundlich B, Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 1989; 32: 817-25.
17. Brennan P, Silman A, Black C et al. On behalf of the U.K. Scleroderma Study Group. Reliability of skin involvement measures in scleroderma. Br J Rheumatol 1992; 31: 457-60.
18. Clements P, Lachenbruch P, Seibold J et al. Inter- and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
19. Rosenbloom J, Feldman G, Freundlich B, Jimenez SA. Inhibition of excessive scleroderma fibroblast collagen production by recombinant γ-interferon: association with a coordinate decrease in types I and III procollagen messenger RNA levels. Arthritis Rheum 1986; 29: 851-6.
20. Polisson RP, Gilkeson GS, Pyun EH et al. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol 1996; 23: 654-8.
21. Fierlbeck G, Rassner G. Rekombinantes Interferon-gamma bei Psoriasis arthrobathica, progressiv systemischer Sklerodermie und Morbus Behcet. Med Klinik 1988; 21: 695-9.
22. Romagnani S. TH1 and TH2 in human diseases. Clin Immunol Immunopathol 1996; 80: 225-35.
23. Silman A, Haurrison M, Brennan P, The Ad Hoc International Group on the Assessment of Disease Outcome in Scleroderma. Is it possible to reduce observer variability in skin score assessment of scleroderma?. J Rheumatol 1995; 22: 1277-80.
24. Gilkeson GS, Polisson RP, Simon L, Smith EA. Gamma interferon in systemic sclerosis: a multicenter trial. Arthritis Rheum 1990; 33 (Suppl. 9): S65 (Abstr.).
25. Pope J. Treatment of systemic sclerosis. Curr Opin Rheumatol 1993; 5: 792-801.
26. Stevens W, Vancheeswaran R, Black CM. The UK Systemic Sclerosis Study Group, Alpha interferon-2a (Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis, a pilot study. Br J Rheumatol 1992; 31: 683-9.
27. White B. Immunologic aspects of scleroderma. Curr Opin Dermatol 1994; 6: 612-15.
28. Mahrle G, Schulze HJ. Recombinant interferon in dermatology. J Invest Dermatol 1990; 95 (Suppl.): 132-7S.
29. Rombaldi A, Young DC, Herman F. Interferon gamma induced expression of IL-2 receptor gene in human monocytes. Eur J Immunol 1987; 138: 3235-41.
30. Clements PJ, Furst DE, Seibold JR, Lachenbruch PA. Controlled trials. Trial design issues. In: Systemic Sclerosis (Clements PJ, Furst DE, eds). Baltimore: Williams & Wilkins. 1996; 515-33.
31. White B, Bauer EA, Goldsmith LA et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). Arthritis Rheum 1995; 38: 351-60.